Abstract:Background Interrogate the impact of IKZF1 deletion on therapy-outcomes of adults with common B-cell acute lymphoblastic leukemia. Methods One hundred sixty-five consecutive adults with common B-cell ALL were tested for IKZF1 deletion and for BCR/ABL. Deletions in IKZF1 were detected using multiplex RQ-PCR, multiplex fluorescent PCR, sequence analysis and multiplex ligation-dependent probe amplification (MLPA). BCR/ABL was detected using RQ-PCR. All subjects received chemotherapy and some also received an allotransplant and tyrosine kinase-inhibitors. Multivariate analyses were done to identify associations between IKZF1 deletion and other variables on non-relapse mortality (NRM), cumulative incidence of relapse (CIR), leukemia-free survival (LFS) and survival. Results Amongst subjects achieving complete remission those with IKZF1 deletion had similar 5-year non-relapse mortality (NRM) (11 % [2–20 %] vs. 16 % [4–28 %]; P = 0.736), a higher 5-year cumulative incidence of relapse (CIR) (55 % [35–76 %] vs. 25 % [12–38 %]; P = 0.004), and worse 5-year leukemia-free survival (LFS) (33 % [16–52 %] vs. 59 % [42–73 %]; P = 0.012) and survival (48 % [33–62 %] vs. 75 % [57–86 %]; P = 0.002). In multivariate analyses IKZF1 deletion was associated with an increased relapse (relative risk [RR] =2.7, [1.4–5.2]; P = 0.002), a higher risk of treatment-failure (inverse of LFS; RR = 2.1, [1.2–3.6]; P = 0.007) and a higher risk of death ( RR = 2.8, [1.5–5.5]; P = 0.002). The adverse impact of IKZF1 deletion on outcomes was stronger in subjects without vs. with BCR-ABL1 and in subjects receiving chemotherapy-only vs. an allotransplant. Conclusions IKZF1 deletion was independently-associated with a higher relapse risk and worse LFS and survival in adults with common B-cell ALL after adjusting for other prognostic variables and differences in therapies. These data suggest IKZF1 deletion may be a useful prognostic variable in adults with common B-cell ALL, especially in persons without BCR-ABL1 and those receiving chemotherapy-only. Transplants appear to overcome the adverse impact of IKZF1 deletion on therapy-outcomes but confirmation in a randomized study is needed. The trial was registered in 2007 with the Beijing Municipal Government (Beijing Municipal Health Bureau Registration N: 2007–1007).

Prognostic significance and treatment strategies for IKZF1 deletion in pediatric B-cell precursor acute lymphoblastic leukemia

Prognosis of pediatric BCP‐ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG‐2016 study

Clinical and Genetic Characteristics of IKZF1 Mutation in Chinese Children with B-Cell Acute Lymphoblastic Leukemia.

The impact of IKZF1 deletion on the prognosis of acute lymphoblastic leukemia: an updated meta-analysis.

Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia

Quantitative Analysis of IKZF1 Gene Deletions in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia: Higher Levels Are Associated with a Poorer Prognosis.

IKZF1 Status As an Independent Prognostic Marker in Adult Common B-Cell Acute Lymphoblastic Leukemia

The Clinical Impact of IKZF1 Mutation in Acute Myeloid Leukemia

[Therapeutic Efficacy of VICP+L-ASP/TKI on Adult Patients with B-ALL].

Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity

Minimal Residual Disease Detection by Next-Generation Sequencing of Different Immunoglobulin Gene Rearrangements in Pediatric B-ALL

Ikzf1 Alterations And Expression Of Crlf2 Predict Prognosis In Adult Chinese Patients With B-Cell Precursor Acute Lymphoblastic Leukemia

Prognostic Significance of IKZF1 Alteration Status in Pediatric B-lineage Acute Lymphoblastic Leukemia: a Meta-Analysis

Characterisation of cells markers associated with IKZF1plus in BCP-ALL

IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia

Clinical Features and Prognostic Impact of TCF3–PBX1 in Childhood Acute Lymphoblastic Leukemia: A Single-Center Retrospective Study of 837 Patients from China

Minimal Residual Disease-guided Risk Restratification and Therapy Improves the Survival of Childhood Acute Lymphoblastic Leukemia: Experience from a Tertiary Children's Hospital in China

The Prognostic Significance of ZNF384 Fusions in Adult Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: A Comprehensive Cohort Study From a Single Chinese Center

What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?

Gene Deletions And Prognostic Values In B-Linage Acute Lymphoblastic Leukemia

Molecular characterization and biomarker identification in paediatric B-cell acute lymphoblastic leukaemia